Search the Newsreel

Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress

Immunovant (IMVT) reported a wider-than-expected net loss of 75 cents per share in Q1 fiscal 2027, surpassing the Zacks Consensus Estimate of a 66-cent loss. Despite no approved products, the company is advancing its lead asset, IMVT-1402, an FcRn inhibitor, through multiple clinical trials …

FMR LLC (IMCR) discloses 4.3M Immunocore shares under amended 13G

FMR LLC and Abigail P. Johnson have reported their beneficial ownership of Immunocore Holdings plc (IMCR) common stock via an amended Schedule 13G filing. FMR LLC beneficially owns 4,307,246 shares, representing an 8.8% stake, with sole dispositive power. Abigail P. Johnson also holds sole …

AC Immune (NasdaqGM:ACIU) Stock Price Shrugs Off Surprise Quarterly Profit

AC Immune (NasdaqGM:ACIU) reported a surprise Q2 2026 profit with basic earnings per share of 0.018701 CHF and revenue of 15.113m CHF, a significant turnaround from a loss in the previous year. Despite this positive financial shift for the Alzheimer and neurodegeneration specialist, the …

Immunovant reports $153.2M net loss, $797.8M cash as of June 30, 2026

Immunovant reported a net loss of $153.2 million and held $797.8 million in cash as of June 30, 2026. The company's R&D expenses increased, while G&A expenses decreased. Immunovant confirmed that the clinical development timelines for IMVT-1402 across six indications remain on track, with …

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36

Stifel has initiated coverage on Lyell Immunopharma, Inc. (LYEL.O) with a buy rating, setting a target price of $36. This announcement comes from Reuters and reflects an analyst's opinion on the company's prospects. The article also includes a disclaimer stating that the content is …

Immunocore (NASDAQ: IMCR) returns to profit as KIMMTRAK revenue climbs

Immunocore (NASDAQ: IMCR) reported a return to profit in the first half of 2026, driven by strong KIMMTRAK sales, with net revenue from therapies climbing to $222.6 million, a 16.0% increase year-over-year. The company posted a first-half net income of $12.2 million, a significant …

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

Immunovant (Nasdaq: IMVT) announced its corporate updates and financial results for the first fiscal quarter ended June 30, 2026. The company's IMVT-1402 clinical development timelines remain on track across six indications, with topline data expected for various trials between calendar years 2026 and 2028. …

Immunovant's $797.8M Cash Provides Runway to Potential Drug Launch

Immunovant (IMVT) reported its fiscal first-quarter 2026 financial results, including a net loss of $153.2 million and R&D expenses of $142.6 million. Despite increased R&D, the company's cash and cash equivalents of $797.8 million as of June 30, 2026, are projected to provide sufficient …

Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss

Immunocore Holdings plc reported a Q2 loss of $0.02 per share, which aligns with FactSet's estimate. This financial update follows an earlier report of their Q2 revenue reaching $115.9 million, surpassing FactSet's estimate of $110.4 million. The company, a United Kingdom-based biotechnology firm, specializes …

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss

Immunovant (IMVT) reported a fiscal Q1 loss of $0.75 per share, which is wider than the FactSet estimate of a $0.65 loss per share. The company is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its pipeline includes product candidates …

Renaissance Technologies LLC Raises Stake in MoonLake Immunotherapeutics $MLTX

ImmuCell (ICCC) Expected to Release Earnings on Thursday

Lyell Immunopharma (LYEL) Earnings Date and Reports 2026 $LYEL

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – FWB:6YG

Immunocore Holdings Plc (FWB:6YG) generated €340.58 million in revenue last year, primarily from its Immunotherapies segment. The United States was the largest geographical contributor, accounting for €218.81 million of the company's revenue. The article highlights the company's top-performing segment and its major market.

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy

Stifel initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a buy rating and a price target of $36.00, citing the potential of its Rondecabtagene autoleucel (Ronde-cel) CAR T-cell therapy. The firm believes Ronde-cel could achieve clinical superiority and regulatory approvals by 2028 and 2030, projecting …

BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU)

AC Immune (NASDAQ:ACIU) Announces Earnings Results, Misses Estimates By $0.09 EPS

Immuneering (NASDAQ:IMRX) Releases Earnings Results

Laurion Capital discloses 6.06% Immunic (IMUX) stake via shares and warrants

Laurion Capital Management LP and its related entities have disclosed a 6.06% beneficial ownership stake in Immunic, Inc. (IMUX) as of June 30, 2026. This stake comprises 839,526 shares, including common stock and shares issuable upon the exercise of warrants. The filing indicates shared …

Immunocore set to report earnings ahead of pivotal trial data

Immunocore Holdings PLC is set to report second-quarter financial results with investors focusing on the commercial performance of its drug KIMMTRAK and the progress of its clinical trial for cutaneous melanoma. Analysts anticipate earnings of $0.01 per share on $110.3 million in revenue. The …

Immunocore Q2 2026 Earnings Preview

* Immunocore (IMCR [https://seekingalpha.com/symbol/IMCR]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is $0.02 [https://seekingalpha.com/symbol/IMCR/earnings/estimates] (+110.0% Y/Y) and the consensus Revenue Estimate is $110.37M (+12.6% Y/Y). * Over the last 3 months, EPS …

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period's loss of 10 cents. Total revenues …

Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 30.9% in the first quarter, now owning 594,712 shares worth $17.9 million. Several other institutional investors also adjusted their positions, with institutional investors and hedge funds collectively owning 84.5% …

AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026Phase 2 VacSYn trial of ACI-7104 in Parkinson’s …

Altimmune to discuss its liver-treatment candidate Aug. 12

Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, including a conference call and webcast at 8:30 a.m. ET to review results and provide a business update. The company is a late clinical-stage biopharmaceutical company developing pemvidutide …

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune, Inc. (Nasdaq: ALT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results and update, which will also be …

AC Immune: Q2 Earnings Snapshot

AC Immune’s Parkinson’s Trial Gets a $4 Million Grant

AC Immune (NASDAQ: ACIU) reported its first-half 2026 financial and corporate update, highlighting a $4 million grant for its Phase 2 VacSYn trial (ACI-7104) for Parkinson’s disease. The company also received a $12 million milestone payment from Takeda for initiating a new cohort in …

Price to book forward of Estrella Immunopharma, Inc. – NASDAQ:ESLA

The article focuses on the "Price to book forward" metric for Estrella Immunopharma, Inc. (NASDAQ: ESLA), a health technology and biotechnology company. It presents a snapshot of the company's financial overview within the TradingView platform, noting that the market was closed at the time …

Partner milestones lift AC Immune (NASDAQ: ACIU) cash and cut loss

AC Immune (ACIU) Beats Q2 Earnings and Revenue Estimates

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Immunovant, Inc. f/k/a Health Sciences Acquisitions Corporation of Class Action Lawsuit and Upcoming Deadline - IMVT; HSACU; HSAC; and HSACW

Pomerantz LLP has filed a class action lawsuit against Immunovant, Inc. (formerly Health Sciences Acquisitions Corporation) and some of its officers, seeking to recover damages for investors who purchased Immunovant securities between October 2, 2019, and February 1, 2021. The lawsuit alleges that Immunovant …

IMUX Technical Analysis & ETF Price Forecast

The article provides a technical analysis of Immunic, Inc. (IMUX), indicating a "Neutral" sentiment based on various technical indicators. While some moving averages suggest a "Buy" signal given the current share price of $14.05, momentum indicators like RSI and MACD are currently neutral. The …

Edgestream Partners L.P. Makes New $1.31 Million Investment in Immunome, Inc. $IMNM

Edgestream Partners L.P. has made a new $1.31 million investment in Immunome, Inc. (NASDAQ:IMNM), acquiring 59,888 shares. This investment highlights continued institutional interest, with other hedge funds also adjusting their positions, bringing total institutional ownership to 44.58%. Despite analyst recommendations for a "Moderate Buy" …

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) reported a Q2 loss of $0.08 per share, surpassing the Zacks Consensus Estimate of a $0.09 loss and showing an 11.11% earnings surprise. The company also beat revenue estimates, posting $51.24 million against an estimated $48.45 million. ImmunityBio's stock has seen a …

ImmunoPrecise Antibodies Ltd. (NASDAQ: HYFT) Stock Price, News & Analysis